This is the authors' abstract. We don't add key points for this paper.
The study of γ‐aminobutyric acid B receptor ( GABA B ) activation is of great interest for several brain disorders. The search of new GABA B receptor agonists has been carried out by many research groups. As a result, Baclofen has become the prototypical GABA B receptor agonist. However, several attempts have been made to modify its structure to generate derivatives with improved activity. In this work, we carried out a theoretical and computational study for a wide range of GABA B receptor agonists reported in the literature. Molecular docking and QSAR techniques were combined by using the interaction energies of the agonists with the key residues of GABA B receptor, as molecular descriptors for the QSAR construction. The resulting mathematical model suggests that the activity of GABA B receptor agonists is influenced by three factors: their shape and molecular size (PW5 and PJI2), their constitutional features ( E LUMO and T(N…O)) and the energy interaction with GABA B receptor ( E TRP278 ). This model was validated by the QUIK , REDUNDANCY and OVERFITTING rules, and its predicted ability was tasted by the Q LOO , Q ASYM , and rules. Finally, six new compounds are proposed ( 35 – 40 ) with high potential to be used as GABA B receptor agonists.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Martínez‐Campos et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: